Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: A phase II study from the GINECO group

British Journal of Cancer

Volumn 100, Issue 4, 2009, Pages 601-607

  Ray Coquard, I ^a   Weber, B ^b   Cretin, J ^c   Haddad Guichard, Z ^d   Levy E ^e   Hardy Bessard, A C ^f   Gouttebel, M C ^g   Geay, J F ^h   Aleba, A ⁱ   Orfeuvre, H ^j   Agostini, C ^k   Provencal, J ^l   Ferrero, J M ^m   Fric, D ⁿ   Dohollou, N ^o   Paraiso, D ^p   Salvat, J ^q   Pujade Lauraine, E ^r  

^a CENTRE LÉON BÉRARD   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

^c Clinique Bonnefon   (France)

^d Centre Hospitalier William Morey   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f Clinique Armoricaine de Radiologie   (France)

^g CENTRE HOSPITALIER DE VALENCE   (France)

^h CENTRE HOSPITALIER DE VERSAILLES   (France)

ⁱ CENTRE HOSPITALIER   (France)

^j Centre Hospitalier Fleyriat   (France)

^k CENTRE HOSPITALIER DE CHAMBÉRY   (France)

^l Centre Hospitalier de la Region d'Annecy   (France)

^m CENTRE ANTOINE LACASSAGNE   (France)

ⁿ Institut Privé de Cancérologie IPC   (France)

^o Polyclinique Bordeaux Nord Aquitaine   (France)

^p Centre Hospitalier de l'Agglomeration Montargoise   (France)

^q Centre Hospitalier de Thonon les Bains   (France)

^r HÔTEL DIEU   (France)

more..

Author keywords

Combination chemotherapy; Gemcitabine; Ovarian cancer; Oxaliplatin; Platinum resistant; Toxicity

Indexed keywords

CARBOPLATIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; OXALIPLATIN; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HEART INFARCTION; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; LEUKOPENIA; LUNG EMBOLISM; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THERAPY RESISTANCE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PLATINUM; TAXOIDS;

EID: 60349105838     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604878     Document Type: Article

References (29)

1. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ (1996) Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2: 521-530
2. Bolis G, Parazzini F, Scarfone G, Villa A, Amoroso M, Rabaiotti E, Polatti A, Reina S, Pirletti E (1999) Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. Gynecol Oncol 72: 60-64
3. Buda A, Floriani I, Rossi R, Colombo N, Torri V, Conte PF, Fossati R, Ravaioli A, Mangioni C (2004) Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br J Cancer 90: 2112-2117
4. Eisenhauer EA, Vermorken JB, Van Glabbeke M (1997) Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments]. Ann Oncol 8: 963-968
5. Faivre S, Le CT, Monnerat C, Lokiec F, Novello S, Taieb J, Pautier P, Lhomme C, Ruffie P, Kayitalire L, Armand JP, Raymond E (2002) Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 13: 1479-1489
6. Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G (2008) Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. JClin Oncol 26: 890-896
7. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881-4886
8. Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehme A, Christen RD, Haas M, MacLeod CL, Howell SB (1997) In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57: 1841-1845
9. Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143-151
10. Franciosi V, Barbieri R, Aitini E, Vasini G, Cacciani GC, Capra R, Camisa R, Cascinu S (2003) Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients. Lung Cancer 41: 101-106
11. Gandara DR, Edelman MJ, Lara PN, Lau DH (2001) Gemcitabine in combination with new platinum compounds: an update. Oncology (Williston Park) 15: 13-17
12. Germano D, Rosati G, Manzione L (2007) Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experience. J Chemother 19: 577-581
13. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin vs topotecan. J Clin Oncol 19: 3312-3322
14. Harnett P, Buck M, Beale P, Goldrick A, Allan S, Fitzharris B, De SP, Links M, Kalimi G, Davies T, Stuart-Harris R (2007) Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study. Int J Gynecol Cancer 17: 359-366
15. Kerbrat P, Lhomme C, Fervers B, Guastalla JP, Thomas L, Basuyau JP, Duvillard P, Cohen-Solal C, Dauplat J, Tournemaine N, Bachelot T, Ray I, Voog E (2001) Standards, options and recommendations for the initial management of patients with malignant ovarian epithelial tumors (abridged version). Gynecol Obstet Fertil 29: 733-742
16. Lhomme C, Ray-Coquard I, Guastalla JP, Bataillard A, Thomas L, Bonnier P, Dargent D, Dohollou N, Ganem G, Lefranc JP, Misset JL, Rixe O, Tchiknavorian X, Tournigand C, Villet R, Bachelot T, Kerbrat P, Fervers B, Basuyau JP, Cohen-Solal-Le Nir C, Morice P, Duvillard P, Voog E (2004) Clinical practice guidelines: standards, options and recommendations for first line medical treatment of patients with ovarian neoplasms (summary report). Bull Cancer 91: 609-620
17. Louvet C, Andre T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de GA (2002) Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 20: 1512-1518
18. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 101: 436-440
19. Markman M, Hoskins W (1992) Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 10: 513-514
20. Mavroudis D, Kourousis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Vardakis N, Samonis G, Georgoulias V (2000) Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report. Semin Oncol 27: 25-30
21. Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M, Gaglia A, Kostopoulou V, Mylonakis N, Skarlos D (2004) Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 15: 493-497
22. Piccart MJ, Green JA, Lacave AJ, Reed N, Vergote I, Bedetti-Panici P, Bonetti A, Kristeller-Tome V, Fernandez CM, Curran D, van GM, Lacombe D, Pinel MC, Pecorelli S (2000) Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 18: 1193-1202
23. Raspagliesi F, Zanaboni F, Vecchione F, Hanozet F, Scollo P, Ditto A, Grijuela B, Fontanelli R, Solima E, Spatti G, Scibilia G, Kusamura S (2004) Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane. Oncology 67: 376-381
24. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E (2002) Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1: 227-235
25. Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P, Stauch M, Paulenz A, Camara O, Keil E, Lichtenegger W (2008) Nonplatinum topotecan combinations vs topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 26: 3176-3182
26. Steer CB, Chrystal K, Cheong KA, Galani E, Marx GM, Strickland AH, Yip D, Lofts F, Gallagher C, Thomas H, Harper PG (2006) Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study. Gynecol Oncol 103: 439-445
27. Theodore C, Bidault F, Bouvet-Forteau N, Abdelatif M, Fizazi K, di Palma M, Wibault P, de Crevoisier R, Laplanche A (2006) A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Ann Oncol 17: 990-994
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [see comments]. J Natl Cancer Inst 92: 205-216
29. Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M, Jakobsen A, Vermorken JB (2000) Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst 92: 1534-1535